Table 5.
Multivariate models predicting an average allopurinol dose change ≥50 mg/day
| Odds Ratio | 95% Confidence Interval Lower limit | 95% Confidence Interval Upper limit | p-value | |
|---|---|---|---|---|
| Degree of renal impairment | ||||
| Stage 2 CKD* | 0.939 | 0.729 | -1.208 | 0.623 |
| Stage 3 CKD* | 1.218 | 0.857 | -1.732 | 0.2723 |
| Stage 4 CKD* | 2.13 | 1.38 | -3.289 | 0.0006 |
| Age | 0.973 | 0.962 | -0.985 | < .0001 |
| Male gender | 0.948 | 0.686 | -1.309 | 0.7455 |
| Geographic region** | ||||
| West | 1.303 | 0.83 | -2.045 | 0.2507 |
| South | 1.314 | 1.019 | -1.693 | 0.0353 |
| Northeast | 1.641 | 1.141 | -2.362 | 0.0076 |
| Thiazide use during follow-up | 1.301 | 1.035 | -1.635 | 0.0244 |
| Charlson-Deyo Comorbidity Index score | 1.164 | 1.059 | -1.279 | 0.0016 |
| Months of allopurinol use | 1.022 | 1.015 | -1.028 | < .0001 |
*The reference group is patients with no CKD.
** The reference group is the Midwest